Jennifer Schofield
Family · Sneads Ferry, NCNPI 1235727264
Payments from drug & device makers
Across 173 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$802
- AstraZeneca$542
- Novo Nordisk$239
- Ironwood Pharmaceuticals, Inc$165
- Pfizer$155
- GSK$97
- plus $998 from 24 others
What the payments were for
- Food & beverage$2,999100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 47 | $802 |
| AstraZeneca | 33 | $542 |
| Novo Nordisk | 14 | $239 |
| Ironwood Pharmaceuticals, Inc | 9 | $165 |
| Pfizer | 9 | $155 |
| GSK | 6 | $97 |
| Novartis | 5 | $83 |
| Grifols USA, LLC | 4 | $81 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $72 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Paratek Pharmaceuticals, Inc. | 4 | $66 |
| Johnson & Johnson | 3 | $63 |
| Amgen | 3 | $62 |
| Lilly USA, LLC | 4 | $62 |
| Collegium Pharmaceutical, Inc. | 3 | $53 |
| Boehringer Ingelheim | 2 | $50 |
| Exact Sciences | 3 | $45 |
| USWM, LLC | 2 | $33 |
| Organon | 1 | $32 |
| Agile Therapeutics, Inc. | 2 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Insulet Corporation | 1 | $27 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Merck | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| G Medical Diagnostic Services, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$2,999 in reported general payments places this provider in the 85th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $13,441 |
| Atorvastatin Calcium | 66 | $892 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $660 |
| Enalapril Maleate | 18 | $396 |
| Levothyroxine Sodium | 38 | $381 |
| Bupropion XlBupropion Hcl | 17 | $375 |
| Gabapentin | 15 | $367 |
| Metoprolol Succinate | 23 | $255 |
| Lisinopril | 56 | $239 |
| Fluticasone Propionate | 12 | $211 |
| Amlodipine Besylate | 33 | $170 |
| Metformin Hcl | 20 | $168 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $95 |
| Rosuvastatin Calcium | 12 | $63 |
| Pantoprazole Sodium | 13 | $59 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $97 | $13,44119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,522 family providers in North Carolina.
Other family in Sneads Ferry
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.